Zabihollah Shoja

Zabihollah Shoja

Auto-generated profile, based on publicly available information

Zabihollah Shoja

Department of Virology Pasteur Institute of Iran Tehran Iran

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
MFMohammad Farahmand
Mohammad Farahmand
MMMohsen Moghoofei
Mohsen Moghoofei
ADAbolfazl Dorost
Abolfazl Dorost
ZSZabihollah Shoja
Zabihollah Shoja
SGsaied ghorbani
saied ghorbani
ATAhmad Tavakoli
Ahmad Tavakoli

15 October 2020 in Reviews in Medical Virology
Verified
Journal Article
Open access
PDF file
AAArash Arashkia
Arash Arashkia
SJSomayeh Jalilvand
Somayeh Jalilvand
NMNasir Mohajel
Nasir Mohajel
AAAtefeh Afchangi
Atefeh Afchangi
KAKayhan Azadmanesh
Kayhan Azadmanesh
F(for the SARS CoV-2 Rapid Response Team of Pasteur Institute of Iran (PII)
for the SARS CoV-2 Rapid Response Team of Pasteur Institute of Iran (PII)
Summary: Coronavirus disease 2019 (Covid‐19) is caused by severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2) which is responsible for a global pandemic that started in late 2019 in Wuhan, China. To prevent the worldwide spread of this highly pathogenic virus, development of an effective and safe vaccine is urgently needed. The SARS‐CoV‐2 and SARS‐CoV share a high degree of genetic and pathologic identity and share safety and immune‐enhancement concerns regarding vaccine development. Prior animal studies with first generation (whole virus‐based) preparations of SARS‐CoV vaccines (inactivated and attenuated vaccine modalities) indicated the possibility of increased infectivity or eosinophilic infiltration by immunization. Therefore, development of second and third generation safer vaccines (by using modern vaccine platforms) is actively sought for this viral infection. The spike (S) protein of SARS‐CoVs is the main determinant of cell entry and tropism and is responsible for facilitating zoonosis into humans and sustained person‐to‐person transmission. Furthermore, ‘S’ protein contains multiple neutralizing epitopes that play an essential role in the induction of neutralizing antibodies (nAbs) and protective immunity. Moreover, T‐cell responses against the SARS‐CoV‐2 ‘S’ protein have also been characterized that correlate to the IgG and IgA antibody titres in Covid‐19 patients. Thus, S protein is an obvious candidate antigen for inclusion into vaccine platforms against SARS‐CoV‐2 viral infection. This manuscript reviews different characteristics of S protein, its potency and ‘state of the art’ of the vaccine development strategies and platforms using this antigen, for construction of a safe and effective SARS‐CoV‐2 vaccine.

28 April 2011 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
SJSomayeh Jalilvand
Somayeh Jalilvand
ZSZabihollah Shoja
Zabihollah Shoja
TATalat Mokhtari Azad
Talat Mokhtari Azad
RNRakhshandeh Nategh
Rakhshandeh Nategh
AGAhmad Gharehbaghian
Ahmad Gharehbaghian
Seroepidemiological surveys show that the prevalence of human herpesvirus 8 (HHV-8) infection mostly varies in various geographical areas and reflects the local incidence of classic and endemic KS, being widespread in sub-Saharan Africa and Mediterranean countries and uncommon in the USA and Northern Europe. In the Middle East only few populations, such as Ashkenazi and Sephardic groups in Israel, have been adequately evaluated for HHV-8 seroprevalence. Among Iranian population a striking higher seroprevalence of HHV8 has been reported among haemodialysis (16.9%), renal transplant recipients (25%) and HIV (45.7%) patients compared to blood donors (2%). Kaposi's sarcoma (KS) is the rarest cancer in Iran, with an annual age-standardized incidence varying from 0.10 to 0.17 per 100,000 in males and from 0.06 to 0.08 per 100,000 in females. KS, however, is one of the most important malignancies in Iranian renal transplanted patients affecting up to 2.4% of organ recipients. The epidemiology of HHV8 and KS in Iran needs further evaluation. While the high prevalence of HHV-8 antibodies in HIV positive and haemodialysis individuals may be attributed to high-risk sexual behavior and polytransfusions, respectively, unknown determinants may be responsible for high seroprevalence of HHV8 and high incidence of KS in solid organ recipients. A global survey on HHV8 seroprevalence in Iran is mandatory to define co-factors associated with HHV8 infection and KS risk in the general Iranian population and in specific patient groups.

25 August 2014 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
SJSomayeh Jalilvand
Somayeh Jalilvand
ZSZabihollah Shoja
Zabihollah Shoja
KNKeramat Nourijelyani
Keramat Nourijelyani
HTHamid Reza Tohidi
Hamid Reza Tohidi
RHRasool Hamkar
Rasool Hamkar

6 January 2019 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
AAAtefeh Afchangi
Atefeh Afchangi
SJSomayeh Jalilvand
Somayeh Jalilvand
NMNasir Mohajel
Nasir Mohajel
SMSayed Mahdi Marashi
Sayed Mahdi Marashi
ZSZabihollah Shoja
Zabihollah Shoja

15 September 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
SJSomayeh Jalilvand
Somayeh Jalilvand
ZSZabihollah Shoja
Zabihollah Shoja
RHRasool Hamkar
Rasool Hamkar
Certain types of human papillomaviruses (HPVs) are undoubtedly involved in genesis of human malignancies. HPV plays an etiological role in cervical cancer, but also in many vaginal, vulvar, anal and penile cancers, as well as head and neck cancers. In addition, a number of non-malignant diseases such as genital warts and recurrent respiratory papillomatosis are attributable to HPV. Moreover, HPV forms have detected in several other cancers including esophageal squamous cell carcinoma, lung, prostate, ovarian, breast, skin, colorectal and urinary tract cancers, but associations with etiology in these cases is controversial. The aim of this systematic assessment was to estimate the prevalence of HPV infection and HPV types in HPV-associated cancers, HPV-related non-malignant diseases and in cancers that may be associated with HPV in Iran. The present investigation covered 61 studies on a variety of cancers in Iranian populations. HPV prevalence was 77.5 % and 32.4% in cervical cancer and head and neck cancers, respectively. HPV was detected in 23.1%, 22.2%, 10.4%, 30.9%, 14% and 25.2% of esophageal squamous cell, lung, prostate, urinary tract cancers, breast and skin cancers, respectively. HPV16 and 18 were the most frequent HPV types in all cancers. The findings of present study imply that current HPV vaccines for cervical cancer may decrease the burden of other cancers if they are really related to HPV.